国邦医药上市4周年：归母净利润增长10.70%，市值较峰值蒸发50.94%

Core Insights - The main business of Guobang Pharmaceutical includes research, production, and sales of products related to pharmaceuticals and animal health products. The pharmaceutical segment accounts for the highest revenue share at 64.87%, followed by the animal health segment at 34.24% [2] Financial Performance - In 2021, Guobang Pharmaceutical achieved a net profit attributable to shareholders of 706 million yuan, which increased to 782 million yuan by 2024, reflecting a cumulative growth of 10.70% over the years. The company has not reported any losses in the past four years [2] - From a revenue perspective, Guobang Pharmaceutical's revenue grew from 4.505 billion yuan in 2021 to 5.891 billion yuan in 2024, indicating an overall upward trend despite some fluctuations during the period [2] - The net profit attributable to shareholders increased from 706 million yuan in 2021 to 782 million yuan in 2024, showing steady improvement amidst fluctuations [2] Market Valuation - Since its listing, Guobang Pharmaceutical's market value has declined. The peak market value reached 26.768 billion yuan on August 3, 2021, with a stock price of 47.9 yuan. As of the close on August 1, the stock price was 23.5 yuan, and the market value was 13.132 billion yuan, representing a decrease of 13.635 billion yuan, or 50.94% from its peak [5]